Journal of International Research in Medical and Pharmaceutical Sciences

Cancer remains a leading cause of global mortality, and conventional treatment modalities such as chemotherapy, radiotherapy, and surgery often suffer from limited tumor specificity, systemic toxicity, and suboptimal patient outcomes. In this context, nanotechnology has emerged as a clinically relevant strategy to enhance therapeutic precision and reduce adverse effects. Several clinically approved nanomedicines, including liposomal doxorubicin (Doxil®), liposomal daunorubicin (DaunoXome®), albumin-bound paclitaxel (Abraxane®), and liposomal irinotecan (Onivyde®), demonstrate the translational potential of nanocarrier-based drug delivery systems by improving pharmacokinetics, tumor targeting, and tolerability. These platforms exemplify how nanoscale engineering can enhance drug solubility, prolong circulation time, and achieve controlled release, thereby improving therapeutic efficacy and patient quality of life. Beyond established formulations, emerging nanotechnological approaches such as nanovaccines, polymeric and metallic nanoparticles, and gene-delivery systems are being explored to augment cancer immunotherapy, photothermal therapy, and photodynamic therapy. Such systems support tumor-specific immune activation, enable targeted cytotoxicity, and facilitate theranostic integration for real-time monitoring of treatment response. However, despite promising preclinical and clinical outcomes, several challenges constrain widespread clinical adoption. These include limited large-scale clinical validation, potential long-term toxicity, manufacturing complexity, regulatory hurdles, high production costs, and variability in biological interactions. Addressing these translational barriers through standardized evaluation protocols, improved safety profiling, and cost-effective manufacturing will be critical for broader clinical integration. Overall, nanotechnology-driven oncology holds substantial promise in bridging experimental innovation with clinical practice, advancing more precise, personalized, and clinically effective cancer therapies.